GLP1RAs tied to greater risk of diabetic retinopathy progression than SGLT2is

In patients with diabetes and established diabetic retinopathy (DR), treatment with glucagon-like peptide 1 receptor agonists (GLP1RAs) is associated with increased risks of DR progression compared with sodium-glucose cotransporter 2 inhibitors (SGLT2is), according to a study published online July 19 in Diabetes, Obesity and Metabolism.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup